

About author, main scientific results and acknowledgments

Dr. Jacob L. Turumin (Iakov L. Tyuryumin), MD, PhD, DMSci, 04.23.1960, **Doctor of Medical Sciences** is engaged by elaboration of the effective pathogenetic proved methods of treatment of the biliary diseases and the pancreatic diseases, directed on decrease of morbidity, on prolongation of complete clinical remission period, on improvement of quality of life of patients after cholecystectomy, on increase of vital activity and life span (Russia).

In 1989-1990 he took an active part in elaboration of the theme "Agent for prophylaxis of stone formation in gallbladder" and of the hepatoprotective agent "Siberian Tea" (Salsola Collina) – Patent No.: RU 2020947 C1.

In 1991 Turumin J.L. successfully defended his Ph.D. thesis: "Role of cholestanol in the pathogenesis of cholesterol cholelithiasis" – Author's certificate No.: SU 1691750 A1.

In 1996 the new model of the pathogenesis of cholesterol cholelithiasis was first presented at the XIV International Bile Acid Meeting "Bile Acids in Hepatobiliary Diseases – Basic Research and Clinical Application" (Freiburg, Germany, 1996).

In 1997 the new conception of the "Role of the Gallbladder in a Human" was first presented at the XIX Congress of the Latin American Federation of the International College of Surgeons (La Paz, Bolivia, 1997).

In 2000 he defended his Doctor's degree thesis: "Mechanism of development of morphological-functional disturbances in the gallbladder and liver in the pathogenesis of cholesterol cholelithiasis".

In 2006 for the first time in the world Dr. Turumin JL (MD, PhD, DMSci) has removed a "large" (25*22 mm) "thick" (4-5 mm) primary melanoma on the left cheek of the young 42 year-old woman without surgical treatment, without radiation therapy, without chemotherapy and without immunotherapy. The tumour was removed by means of local treatment with use of drops of disulfiram solution and drops of CuSO₄ solution. Local, transit, regional and distant metastases are absent since 2006, i.e. duration of disease-free period is 7 years.

In 2007 a new algorithm of pathogenetic treatment of the biliary diseases was first presented at Falk Symposium No.161 "Future Perspectives in Gastroenterology" (Dresden, Germany, 2007) – Patent No.: RU 2348405 C2.

In 2010-2012 he took an active part in elaboration of the theme "Model of formation of functional disorders in the sphincter of Oddi in patients with biliary diseases and pancreatic diseases and the algorithm of the pathogenetic treatment".

In 2010-2012 he took an active part in elaboration and in completion of the theme "The algorithm of the pathogenetic treatment of symptomatic (with biliary pain) biliary diseases with concomitant functional disorders in sphincter of Oddi".

In 2010-2012 he took an active part in elaboration of the theme "The algorithm of the pathogenetic treatment of primary and metastatic melanoma".

In 2012-2013 he took an active part in elaboration and in completion of the theme "Functional disorders in the sphincter of Oddi and possibly reflux associated diseases in the hepato-biliary-cholecysto-pancreatico-duodeno-gastro-esophageal region".

In 2013 the article "Turumin JL, Shanturov VA, Turumina HE. The role of the gallbladder in humans. *Revista de Gastroenterología de México*. 2013; 78(3): 177-187" was published.



At present the algorithm of pathogenetic treatment of the biliary diseases is used in 105 countries of the North America, Central America and South America, Europe and Asia Pacific, Africa and Middle East (Russia, Canada, USA, Barbados (West Indies), Mexico, Panama, Puerto Rico, Venezuela, Peru, Bolivia, Colombia, Costa Rica, Dominican Republic, Ecuador, El Salvador, Guatemala, Nicaragua, Paraguay, Uruguay, Brazil, Argentina, Chile, Norway, Sweden, Finland, Great Britain, Ireland, Island, Denmark, Belgium, Netherlands, Austria, Germany, Switzerland, France, Spain, Portugal, Luxemburg, Italy, Israel, Bosnia and Herzegovina, Croatia, Macedonia, Serbia, Slovenia, Greece, European Countries, Bulgaria, Czech Republic, Slovakia, Hungary, Romania, Poland, Estonia, Latvia, Lithuania, Belarus, Ukraine, Moldova, Armenia, Georgia, Azerbaijan, Kazakhstan, Uzbekistan, Tajikistan, Kyrgyzstan, Turkey, Iraq, Iran, Pakistan, India, Bangladesh, Sri Lanka, Nepal, Philippines, Singapore, Thailand, Bangladesh, Indonesia, Malaysia, Vietnam, Hong Kong, Taiwan, China, Mongolia, South Korea, Japan, Australia, New Zealand, Madagascar, Egypt, Algeria, Ghana, Nigeria, Morocco, Tunisia, Lebanon, Tanzania, Qatar, Bahrain, United Arab Emirates, Oman, Saudi Arabia, Palestinian Territories, Yemen, Libya, Syria, and South Africa, Botswana).

In 2001-2005 Dr. Jacob L. Turumin worked at the Oncology Department of Irkutsk State Institute of Advanced Training of Doctors as an assistant, an assistant professor, and a professor.

In 2005-2006 Dr. Jacob L. Turumin worked as the Deputy Chief Officer of the Center of Immunotherapy and Cellular Technologies (Kaliningrad).

In 2006-2013 Dr. Jacob L. Turumin worked in the Irkutsk Institute of Surgery (Scientific Centre of Reconstructive-Restorative Surgery, Siberian Division, Russian Academy of Medical Sciences, Irkutsk, Russia) as a senior research fellow, and as a leading research fellow.

In general, as a result of the scientific activity, 205 scientific works have been published, 6 patents, 2 monographs, 60 abstracts were presented on 23 international congresses and symposiums.

Main scientific results were presented at:

1. 15th United European Gastroenterology Week (Paris, France, 2007).
2. Asian Pacific Digestive Week 2007 (Kobe, Japan, 2007);
3. Falk Symposium No.161 "Future Perspectives in Gastroenterology" (Dresden, Germany, 2007);
4. XIXth Belgian Week of Gastroenterology (Oostende, Belgium, 2007);
5. XII Japan-Russian Medical Exchange Symposium (Krasnoyarsk, Russia, 2005);
6. XII World Congress of Gastroenterology (Montreal, Canada, 2005);
7. The Eleventh International Symposium of the Japan-Russia Medical Exchange 2004 (Niigata, Japan, 2004);
8. 40th Annual Meeting of Canadian Association of Gastroenterology, 15th Annual Meeting of Canadian Association for the Study of the Liver (Vancouver, Canada, 1999).
9. 8th International Congress of Cardiovascular Pharmacotherapy (Amsterdam, The Netherlands, 1999);
10. 11th World Congress of Gastroenterology (Vienna, Austria, 1998);
11. 3rd World Congress of the International Hepato-Pancreato-Biliary Association (Madrid, Spain, 1998);
12. XV International Bile Acid Meeting "Bile Acids and Cholestasis" (Titisee, Germany, 1998);
13. XIX Congress of the Latin American Federation of the International College of Surgeons (La Paz, Bolivia, 1997);
14. XXX World Congress of the International College of Surgeons (Kyoto, Japan, 1996);
15. XIV International Bile Acids Meeting "Bile Acids in Hepatobiliary Diseases – Basic Research and Clinical Application" (Freiburg, Germany, 1996);
16. IV Japan-Russian Medical Exchange Symposium (Irkutsk, Russia, 1996);
17. Falk Symposium No. 84: "Bile acids – Cholestasis – Gallstones" (Berlin, Germany, 1995);
18. 2nd International Conference on Gallstones: Causes and Management (Tel Aviv, Israel, 1995);
19. XIX Congress of the International College of Surgeons (Tenerife, Spain, 1995);
20. The 1995 Winter Conference of United States Section of International College of Surgeons "Supercharge Your Practice" (Puerto Rico, USA, 1995);
21. XIII International Bile Acid Meeting "Bile Acids in Gastroenterology: Basic and Clinical Advances" (San Diego, USA, 1994);
22. 10th Congress of Gastroenterology (Los Angeles, USA, 1994);
23. 41th Annual Postgraduate Course and Meeting of American Association for the Study of Liver Disease "Biliary Lipids, Proteins and Gallstone Formation" (Chicago, USA, 1990).

Main scientific publications:

1. Turumin JL, Shanturov VA, Turumina HE. The role of the gallbladder in humans // **Revista de Gastroenterología de México. 2013**; 78(3): 177-187.
2. Golubev SS, Kozlova NM, Turumin JL, Raevskaja LJu. Increased level of cyclooxygenase-2 expression in the gallbladder wall of patients with chronic calculous cholecystitis // **Gut. 2007**; 56: (Suppl. 3); Endoscopy; 29(Suppl. 1): P. 280 Abstr. G-446.
3. Turumina HE, Kozlova NM, Turumin JL. Decreased portal blood flow in the patients with biliary diseases // **Gut. 2007**; 56: (Suppl. 3); Endoscopy; 29(Suppl. 1): P. 280 Abstr. G-447.
4. Kozlova NM, Turumin JL, Galeev YM, Popov MV. Functional disorders of hepatobiliary system in the patients with biliary diseases // **Gut. 2007**; 56: (Suppl. 3); Endoscopy; 29(Suppl. 1): P. 280 Abstr. G-448.
5. Turumin JL, Kozlova NM. Clinical effects of the pathogenetic treatment of patients with chronic acalculous cholecystitis // **Gut. 2007**; 56: (Suppl. 3); Endoscopy; 29(Suppl. 1): P. 280 Abstr. G-449.
6. Kulinsky VI, Kozlova NM, Turumin JL, Leonova ZA. The changes of the blood glutathione system in patients with biliary diseases // Asian Pacific Digestive Week 2007 (**Kobe, Japan, 2007**): Abstr. A162 (P-060).
7. Turumin JL, Kozlova NM, Utyasheva EB. The serum lipid concentrations in patients with biliary diseases // Asian Pacific Digestive Week 2007 (**Kobe, Japan, 2007**): Abstr. A163 (P-061).
8. Turumin JL, Kozlova NM. The clinical aspects of the pathogenetic treatment of patients with chronic acalculous cholecystitis // Asian Pacific Digestive Week 2007 (**Kobe, Japan, 2007**): Abstr. A163 (P-062).
9. Turumina HE, Kozlova NM, Turumin JL. The changes of the portal blood flow in patients with biliary diseases // Asian Pacific Digestive Week 2007 (**Kobe, Japan, 2007**): Abstr. A164 (P-066).
10. Golubev SS, Kozlova NM, Turumin JL, Raevskaja LJu. High expression of cyclooxygenase-2 in the gallbladder wall of patients with chronic calculous cholecystitis // Asian Pacific Digestive Week 2007 (**Kobe, Japan, 2007**): Abstr. A164 (P-067).
11. Kosilko SA, Kozlova NM, Turumin JL. The immunological changes in patients with biliary diseases // Asian Pacific Digestive Week 2007 (**Kobe, Japan, 2007**): Abstr. A164 (P-068).
12. Kozlova NM, Turumin JL, Galeev YM, Popov MV. The functional state of hepato-biliary system in patients with chronic acalculous cholecystitis and nonfunctioning gallbladder // Asian Pacific Digestive Week 2007 (**Kobe, Japan, 2007**): Abstr. A254 (P-088).
13. Kozlova NM, Turumin JL, Galeev YM, Popov MV. The functional state of hepato-biliary system in patients with chronic calculous cholecystitis in the stage of exacerbation // Asian Pacific Digestive Week 2007 (**Kobe, Japan, 2007**): Abstr. A265 (P-089).
14. Turumin JL, Kozlova NM. Restoration of the functional and metabolic state of the hepato-biliary system in patients with chronic acalculous cholecystitis after pathogenetic treatment // Asian Pacific Digestive Week 2007 (**Kobe, Japan, 2007**): Abstr. A255 (P-090).
15. Kozlova NM, Turumin JL, Galeev YM, Popov MV. The alteration of the functional state of hepato-biliary system in patients with biliary disease // Asian Pacific Digestive Week 2007 (**Kobe, Japan, 2007**): Abstr. A255 (P-091).
16. Kosilko SA, Kozlova NM, Turumin JL. Increase of the serum IgA and circulating immune complexes in the patients with biliary diseases // Falk Symposium No.161 "Future Perspectives in Gastroenterology" (**Dresden, Germany, 2007**): Abstr. P. 14.
17. Kulinsky VI, Kozlova NM, Turumin JL, Leonova ZA. Increase of the blood glutathione in the patients with biliary diseases // Falk Symposium No.161 "Future Perspectives in Gastroenterology" (**Dresden, Germany, 2007**): Abstr. P. 15.
18. Turumin JL, Kozlova NM. Clinical aspects of the effective pathogenetic treatment of patients with chronic acalculous cholecystitis // Falk Symposium No.161 "Future Perspectives in Gastroenterology" (**Dresden, Germany, 2007**): Abstr. P. 19.
19. Turumina HE, Kozlova NM, Turumin JL. Decrease of the portal blood flow in the patients with biliary diseases // Falk Symposium No.161 "Future Perspectives in Gastroenterology" (**Dresden, Germany, 2007**): Abstr. P. 20.
20. Golubev SS, Kozlova NM, Turumin JL, Raevskaja LJu. The expression of cyclooxygenase-2 in the gallbladder wall of the patients with chronic calculous cholecystitis // **Acta Gastroenterol Belg. 2007**; 70(Fasc. 1): Abstr. 31.
21. Turumin JL, Kozlova NM. The restoration of the functional and metabolic state of hepato-biliary system in the patients with chronic acalculous cholecystitis before and after pathogenetic treatment // **Acta Gastroenterol Belg. 2007**; 70(Fasc. 1): Abstr. 32.
22. Kozlova NM, Turumin JL, Galeev YM, Popov MV. The functional state of hepato-biliary system in the patients with chronic calculous cholecystitis in the stage of exacerbation // **Acta Gastroenterol Belg. 2007**; 70(Fasc. 1): Abstr. 33.
23. Turumin JL, Kozlova NM. The clinical aspects of the pathogenetic treatment of the patients with chronic acalculous cholecystitis // **Acta Gastroenterol Belg. 2007**; 70(Fasc. 1): Abstr. 34.
24. Kulinsky VI, Kozlova NM, Turumin JL, Leonova ZA. The blood glutathione system in the

- patients with biliary diseases // *Acta Gastroenterol Belg.* 2007; 70(Fasc. 1): Abstr. 35.
25. Turumina HE, Kozlova NM, Turumin JL. The changes of the portal blood flow in the patients with biliary diseases // *Acta Gastroenterol Belg.* 2007; 70(Fasc. 1): Abstr. 36.
 26. Kosilko SA, Kozlova NM, Turumin JL. The immunological changes in the patients with biliary diseases // *Acta Gastroenterol Belg.* 2007; 70(Fasc. 1): Abstr. 37.
 27. Turumin JL, Kozlova NM, Utyasheva EB. The serum lipids level in the patients with biliary diseases // *Acta Gastroenterol Belg.* 2007; 70(Fasc. 1): Abstr. 38.
 28. Kozlova NM, Turumin JL, Galeev YM, Popov MV, Kulinsky VI, Leonova ZA, Madaev VV. The functional disorders in liver and gallbladder in the patients with biliary diseases // XII Japan-Russian Medical Exchange Symposium (*Krasnoyarsk, Russia, 2005*): P. 527-528.
 29. Kozlova NM, Turumina HE, Turumin JL, Utyasheva EB, Barachovscaya TV. The peculiarities of the serum lipids spectrum and the portal blood flow in the patients with biliary diseases // XII Japan-Russian Medical Exchange Symposium (*Krasnoyarsk, Russia, 2005*): P 528-529.
 30. Kozlova NM, Turumina HE, Turumin JL, Utyasheva EB. The increase of the serum lipids level and decrease of the portal blood flow in the pts with biliary diseases // XII World Congress of Gastroenterology (*Montreal, Canada, 2005*): Abstr. 146 173 P.
 31. Kozlova NM, Kulinsky VI, Galeev YM, Popov MV, Leonova ZA, Turumin JL. Chronic intrahepatic and intragallbladder cholestasis are two main factors for gallstones formation // XII World Congress of Gastroenterology (*Montreal, Canada, 2005*): Abstr. 146 131 P.
 32. Turumin JL, Shanturov VA, Goldberg OA, Turumina HE, Kozlova NM. Role of the gallbladder in human // The Eleventh International Symposium of the Japan-Russia Medical Exchange 2004: Abstract (II) Supplement (*Niigata, Japan, 2004*): Abstr. 367.
 33. Kozlova NM, Turumin JL, Kulinsky VI, Leonova ZA, Jacobson YaA. The influence of Essliver fortae on the lipid spectrum and the glutathione system in blood in the patients with biliary pathology // The Eleventh International Symposium of the Japan-Russia Medical Exchange 2004: Abstract (II) Supplement (*Niigata, Japan, 2004*): Abstr. 368.
 34. Kozlova NM, Kulinsky VI, Leonova ZA, Turumin JL. The changes in the blood glutathione system in the patients with biliary diseases after pathogenetic treatment // The Eleventh International Symposium of the Japan-Russia Medical Exchange 2004: Abstract (II) Supplement (*Niigata, Japan, 2004*): Abstr. 369.
 35. Cherkashina AL, Reut JuA, Shanturov VA, Turumina HE, Tarabrin AL, Turumin JL. Relationships between serum lipids and the function of the liver and gallbladder in patients with ischaemic heart disease // 8th International Congress on Cardiovascular Pharmacotherapy (*Amsterdam, The Netherlands, 1999*): Abstr. 79 P.
 36. Lepekhova SA, Goldberg OA, Turumin JL, Aparcin KA. Liver structure and functions restore after xenotransplantation of embryonic hepatocytes in acute toxic injury // XXVth Pan American Congress of Digestive Diseases. Gastr-99 of the Canadian Association of Gastroenterology (*Vancouver, Canada, 1999*): Abstr. 350 P.
 37. Shanturov VA, Turumin JL, Chikotejev SP, Tarabrin AL. Relationships between serum lipids before and after cholecystectomy in patients with gallstone disease // XV International Bile Acid Meeting "Bile Acids and Cholestasis" (*Titisee, Germany, 1998*): Abstr. 73 P.
 38. Shanturov VA, Turumin JL, Chikotejev SP, Tarabrin AL. Relationships between serum lipids before and after cholecystectomy in patients with gallstone disease // 11th World Congress of Gastroenterology (*Vienna, Austria, 1998*): Abstr. 1254 P.
 39. Turumin JL, Shanturov VA. Role of the gallbladder in mammals // XIX Congress of the Latin American Federation of the International College of Surgeons (*La Paz, Bolivia, 1997*): Abstr. 53.
 40. Maltsev AB, Shanturov VA, Turumin JL, Turumina EA, Chizhova EA. Nonsurgical treatment of destructive cholecystitis // XXX World Congress of the International college of Surgeons (*Kyoto, Japan, 1996*): Abstr. 83.
 41. Shanturov VA, Turumin JL, Chikotejev SP, Tarabrin AL. The decrease of the serum lipids after cholecystectomy in-patients with hypercholesterolemia IIa and gallstone disease // XIV International Bile Acid Meeting "Bile Acids in Hepatobiliary Diseases – Basic Research and Clinical Application" (*Freiburg, Germany, 1996*): Abstr. 100P.
 42. Shanturov VA, Turumin JL, Tarabrin AL, Maltsev AB, Turumina EA. The change of the serum lipids after contact chemical litholysis of cholesterol gallstones by MTBE // XIV International Bile Acid Meeting "Bile Acids in Hepatobiliary Diseases – Basic Research and Clinical Application" (*Freiburg, Germany, 1996*): Abstr. 101P.
 43. Turumin JL, Shanturov VA. Pathogenesis and treatment of cholesterol gallstone disease // XIV International Bile Acid Meeting "Bile Acids in Hepatobiliary Diseases – Basic Research and Clinical Application" (*Freiburg, Germany, 1996*): Abstr. 104P.
 44. Turumin JL, Shanturov VA. The disturbance of the gallbladder bile formation in-patients with cholesterol gallstone disease // XIV International Bile Acid Meeting "Bile Acids in Hepatobiliary Diseases – Basic Research and Clinical Application" (*Freiburg, Germany, 1996*): Abstr. 105P.
 45. Turumin JL, Shanturov VA, Chikotejev SP, Tarabrin AL. Low level of Ch-HDL as risk factor for cholesterol gallstone disease // XIV International Bile Acid Meeting "Bile Acids in Hepatobiliary Diseases – Basic Research and Clinical Application" (*Freiburg, Germany, 1996*):

- Abstr. 106P.
46. Maltsev AB, Shanturov VA, Chizhova EA, Turumina EA, **Turumin JL**. The modern approaches in the treatment of destructive cholecystitis // The 4th Russian-Japan International Medical Symposium (**Irkutsk, Russia, 1996**): Abstr. 114P.
 47. **Turumin JL**, Shanturov VA, Chikotejev SP, Grigorjev EG. I. Transformation of anhydrous cholesterol (ChA) into cholesterol monohydrate (ChM) // Falk Symposium No. 84: "Bile acids – Cholestasis – Gallstones. Advances in Basic and Clinical Bile Acid Research" (**Berlin, Germany, 1995**): Abstr. 4P.
 48. **Turumin JL**, Shanturov VA, Chikotejev SP, Grigorjev EG. II. Working hypothesis: cholesterol exchange physiology in normal // Falk Symposium No. 84: "Bile acids – Cholestasis – Gallstones. Advances in Basic and Clinical Bile Acid Research" (**Berlin, Germany, 1995**): Abstr. 5P.
 49. **Turumin JL**, Shanturov VA, Chikotejev SP, Grigorjev EG. III. Working hypothesis: cholesterol exchange pathophysiology in cholesterol gallstone disease // Falk Symposium No. 84: "Bile acids – Cholestasis – Gallstones. Advances in Basic and Clinical Bile Acid Research" (**Berlin, Germany, 1995**): Abstr. 6P.
 50. **Turumin JL**, Shanturov VA, Chikotejev SP, Grigorjev EG. IV. Working hypothesis: cholesterol exchange pathophysiology in hypercholesterolemia // Falk Symposium No. 84: "Bile acids – Cholestasis – Gallstones. Advances in Basic and Clinical Bile Acid Research" (**Berlin, Germany, 1995**): Abstr. 7P.
 51. Shanturov VA, **Turumin JL**, Chikotejev SP, Tarabrin AL, Maltsev AB. The change of the serum lipids after cholecystectomy (CE) in patients with gallstone disease (GSD) // Falk Symposium No. 84: "Bile acids – Cholestasis – Gallstones. Advances in Basic and Clinical Bile Acid Research" (**Berlin, Germany, 1995**): Abstr. 42P.
 52. Shanturov VA, **Turumin JL**, Maltsev AB, Turumina EA. Chemical litholysis of cholesterol gallstones in the management of destructive cholecystitis // Falk Symposium No. 84: "Bile acids – Cholestasis – Gallstones. Advances in Basic and Clinical Bile Acid Research" (**Berlin, Germany, 1995**): Abstr. 57P.
 53. Shanturov VA, **Turumin JL**, Chikotejev SP, Tarabrin AL, Maltsev A.B. The change of the serum lipids after cholecystectomy (CE) in patients with gallstone disease (GSD) // 2nd International Conference on Gallstones: Causes and Management (**Tel Aviv, Israel, 1995**): Abstr. 15P.
 54. Shanturov VA, **Turumin JL**, Maltsev AB, Turumina EA. Interventional ultrasonography in the treatment of destructive cholecystitis // XIX Congress of the International College of Surgeons (**Tenerife, Spain, 1995**): Abstr. 12.
 55. Shanturov VA, **Turumin JL**, Maltsev AB, Turumina EA. CT and USG in the diagnosis of hepatic hemobilimas (HHB) // XIX Congress of the International College of Surgeons (**Tenerife, Spain, 1995**): Abstr. 14.
 56. Shanturov VA, **Turumin JL**, Maltsev AB, Turumina EA. Chemical litholysis of cholesterol gallstones in the treatment of destructive cholecystitis // The 1995 Winter Conference of United States Section of International College of Surgeons "Supercharge Your Practice" (**Puerto Rico, USA, 1995**): Abstr. 14.
 57. **Turumin JL**, Shanturov VA, Chikotejev SP, Grigorjev EG. III. A new concept on the pathogenesis of the cholesterol gallstone disease // Falk Symposium No. 80. XIII International Bile Acid Meeting "Bile Acids in Gastroenterology: Basic and Clinical Advances" (**San Diego, USA, 1994**): Abstr. 123.
 58. **Turumin JL**, Shanturov VA, Chikotejev SP, Grigorjev EG. I. Molecular peculiarities of anhydrous cholesterol transformation into cholesterol monohydrate // X World Congresses of Gastroenterology (**Los Angeles, USA, 1994**): Abstr. 2581P.
 59. **Turumin JL**, Shanturov VA, Chikotejev SP, Grigorjev EG. II. A new concept of cholesterol exchange physiology // X World Congresses of Gastroenterology (**Los Angeles, USA, 1994**): Abstr. 2582P.
 60. **Turumin JL**, Shanturov VA, Chikotejev SP, Grigorjev EG. III. A new concept on the pathogenesis of the cholesterol gallstone disease // X World Congresses of Gastroenterology (**Los Angeles, USA, 1994**): Abstr. 2583P.
 61. Kodati VR, Tu AT, Nath R, **Turumin JL**. Analysis of urinary calculi of mixed and unusual composition: Raman spectroscopic investigation // **Applied Spectroscopy**. 1993; 47(3): 334-337.
 62. Kodati VR, Tomasi GE, **Turumin JL**, Tu AT. Raman spectroscopic identification of phosphate-type kidney stones // **Applied Spectroscopy**. 1991; 45(4): 581-583.
 63. **Turumin JL**, Nikiforov SB, Gritskikh GL, Chupin SP. The cholestanol/cholesterol ratio is increased in the bile of patients with cholesterol gallstones and in the centers of stones (abstract) // **Hepatology**. 1990, 12(4, Part 2): A258.
 64. Kodati VR, Tomasi GE, **Turumin JL**, Tu AT. Raman spectroscopic identification of calcium-oxalate-type kidney stone // **Applied Spectroscopy**. 1990; 44(8): 1408-1411.
 65. Kodati VR, Tu A, **Turumin JL**. Raman spectroscopic identification of uric-acid-type kidney stone // **Applied Spectroscopy**. 1990; 44(7): 1134-1136.
 66. Krikshtopaitis MJ, Chupin SP, **Turumin JL**, Nikiforov SB, Salenko VL, Kun OB, Vjalkov AI,

- Fedorova LS. Capillary gas chromatographic determination of cholestanol/cholesterol concentration ratio in human bile and gallstones // *Hepatology RLR*. 1989; 19(2): VIII-IX.
67. Krikshtopaitis MJ, Chupin SP, Turumin JL, Nikiforov SB, Salenko VL, Kun OB, Vjalkov AI, Fedorova LS. Hypercholestanolcholia – a risk indicator in the pathogenesis of cholesterol gallstone disease // *Hepatology RLR*. 1989; 19(2): X-XI.
68. Krikshtopaitis MJ, Chupin SP, Turumin JL, Nikiforov SB, Salenko VL, Kun OB, Vjalkov AI, Fedorova LS. The influence of noncholesterol bile sterols on the cholesterol monohydrate crystal nucleation // *Hepatology RLR*. 1989; 19(2): XII-XIII.

Patents and Author's certificates (Russia)

1. Method of treatment of chronic cholecystitis exacerbation (**Celecoxib**): Patent RU 2348405 C2 // Publication Date: **2009.03.10** Bull. №7 / Kozlova NM, Tjurjumin JL.
2. Method of treatment of patients with calculous cholecystitis (**MTBE**): Patent RU 2129026 C1 // Publication Date: **1999.04.20** / Shanturov VA, Tjurjumin JL, Maltsev AB.
3. Method of determination of calcium bilirubinate granules precipitation (**ultraviolet spectroscopy**): Patent RU 2028616 C1 // Publication Date: **1995.02.09** / Gritskikh GL, Tjurjumin JL, Nikiforov SB, Sarapulova GI, Chupin SP.
4. Agent for prophylaxis of stone formation in gallbladder (**Salsola collina Pall.**): Patent RU 2020947 C1 // Publication Date: **1994.10.15** / Semenov AA, Kuznetsov IG, Sychina AI, Tjurjumin JL, Nikiforov SB, Lokheh EV.
5. Method of diagnostics of cholesterol gallstone disease (**infrared spectroscopy**): Author's certificate SU 1714505 A1 // Publication Date: **1992.02.23** Bull. №7 / Chupin SP, Sarapulova GI, Gritskikh GL, Frolov JuL, Tjurjumin JL, Nikiforov SB.
6. Method of forecasting of cholesterol gallstone disease (**gas-liquid chromatography, cholestanol/cholesterol ratio**): Author's certificate SU 1691750 A1 // Publication Date: **1991.11.15** Bull. №42 / Chupin SP, Tjurjumin JL, Nikiforov SB, Salenko VL, Kun OB, Vjalkov AI.

Acknowledgments

I am sincerely grateful for scientific discussion of research work which took place in 1988-1998, and for kindly presented scientific articles by Professors **M.C. Carey** (Harvard University, Boston, USA), **J.L. LaMont** (Boston University School of Medicine, Boston, USA), **R.T. Holzbach** (Cleveland Clinic Foundation, Cleveland, USA), **S.P. Lee** (Veterans Administration Medical Center, Seattle, USA), **A.F. Hofmann** (University of California, San Diego, La Jolla, USA), **H. Fromm** (The G. Washington University Medical Center, Washington, USA), **H.A. Pitt** (Indiana University School of Medicine, Indianapolis, USA), **G. Salen** (University of Medicine, Newark, USA), **P.F. Malet** (Hospital of the University of Pennsylvania, Philadelphia, USA), **W.E. Connor** (Oregon Health Sciences University, Portland, USA), **B.R. MacPherson** (Department of Anatomy and Neurobiology, University of Kentucky, Lexington, USA), **P.R.C. Harvey** and **S.M. Strasberg** (Mount Sinai Hospital, Toronto, Canada), **F. Nervi** (Pontificia Universidad Católica de Chile, Santiago, Chile), **J.C. Montet** and **J.C. Hauton** (U31 and U130 INSERM, Marseille, France), **A.K. Groen**, **J.A.G. Drapers** and **G.N.J. Tytgat** (Academic Medical Centre, Amsterdam, The Netherlands), **B.J. Koopman** (University Hospital, Groningen, The Netherlands), **G.P. Van Berge-Henegouwen** and **M.F.J. Stolk** (University Medical Center Utrecht, Utrecht, The Netherlands), **R.H. Dowling** (St. Thomas' Hospital Campus, London, England, UK), **T.C. Northfield** (St. George's Hospital, London, UK), **T.A. Miettinen** (University of Helsinki, Helsinki, Finland), **I. Bjorkhem** (Hudding University Hospital, Huddinge, Sweden), **S. Sahlin**, **K. Einarsson** and **C. Einarsson** (Karolinska Institutet, Stockholm, Sweden), **K. Nilsell** (Karolinska Institute, Huddinge University Hospital, Stockholm, Sweden), **M.S. Buchmann** (institute of Clinical Biochemistry, Rikshospital, Oslo, Norway), **U. Wosiewitz** (University Hospital, Frankfurt, Germany), **D. Jungst** (Klinikum Grosshadern, Munich, Germany), **G. Paumgartner** (University of Munich, Munich, Germany), **K. Chijiwa** (Miyazaki University School of Medicine, Kiyotake, Miyazaki, Japan), **J. Shoda** (Institute of Clinical Medicine, The University of Tsukuba, Ibaraki, Japan), **S. Tazuma** (Hiroshima University Hospital and Graduate School of Biomedical Sciences, Hiroshima, Japan) and etc.

I would like to express my feeling of gratitude towards to Professor **J.D. Ostrow** (Veterans Administration Lakeside Medical center, Chicago, USA) for the scientific discussion and help in publishing the theses at the 41th Annual Postgraduate Course and Meeting of American Association for the Study of Liver Disease “Biliary Lipids, Proteins and Gallstone Formation” (Chicago, USA, 1990).

Also, I would like to express my appreciation to Professor **A. Tu** (Colorado State University, Colorado, USA for help in publishing the article.

I would like to thank Professor **M.J. Krikshtopaitis** (Vilnius University, Vilnius, Lithuania) for scientific discussion on cholestanol, and also for help in the publishing articles.

The author shows deep respect towards **Dr. Dr. H. Falk** and **Falk Foundation e.V.** for kindly presented the chemical reagents (in 1989-1993) and scientific information (in 1989-1995), and also

for opportunity to participate in Falk-Symposiums, as well.

I would like to express my deepest gratitude to **Dr. Horst-Dietmar Tauschel** (**Dr. Falk Pharma GmbH**) for constant help and support in realization of different scientific researches (in 1991-1995 and in 2007), full-fledged scientific discussion, which took place in 1988-2009.

I am most grateful to Professor **V.A. Shanturov** (Institute of Surgery, the Scientific Centre of Reconstructive-restorative Surgery, Siberian Division, Russian Academy of Medical Science) for constant help and support in realization of different scientific investigations, full-fledged scientific discussion, which took place in 1988-2001.

I would like to express my appreciation for critical remarks of some fragments of scientific work (2001-2009) and kindly presented scientific articles to Professors **R.V. Rege** (UT Southwestern Medical Center at Dallas, Dallas, Texas, USA), **H.A. Pitt** (Indiana University School of Medicine, Indianapolis, USA), **J.D. Ostrow** (Univ. Washington Medical Center, Seattle, WA, USA), **K.J. Maurer** (Massachusetts Institute of Technology, Cambridge, USA), **E.A. Shaffer** (University of Calgary, Calgary, Alberta, Canada), **F. Nervi** (Pontificia Universidad Católica de Chile, Santiago, Chile), **N. Mendez-Sánchez** (Medica Sur Clinic and Foundation, Mexico City, Mexico), **F.M. Konikoff** (Tel Aviv Sourasky Medical Center and Minerva Center for Cholesterol Gallstones and Lipid Metabolism in the Liver, Tel Aviv University, Tel Aviv, Israel), **C. Einarsson** (Karolinska University Hospital Huddinge, Stockholm, Sweden), **D. Jungst** (Klinikum Grosshadern, Munich, Germany), **J. Shoda** (Institute of Clinical Medicine, The University of Tsukuba, Ibaraki, Japan), **M. Makishima** (Nihon University School of Medicine, Tokyo, Japan), **T. Mori** (School of Medicine, Kyorin University, Tokyo, Japan), **F. Lammert** (University Hospital Bonn, University of Bonn, Bonn, Germany), **Tian-Quan HAN** (Shanghai Institute of Digestive Surgery, Shanghai Jiaotong University School of Medicine, Shanghai, China), **A.M.M. Eggermont** (Erasmus University Medical Center, Daniel Den Hoed Cancer Center, Rotterdam, The Netherlands), **D.L. Morton** (John Wayne Cancer Institute at Saint John's Health Center, Santa Monica, USA), and etc.

I am very much grateful to **Alexei F. Kuznetsov** and **Natasha Kuznetsova** for their help in making this web-site, and also for scientific discussion and some questions that made the author have a look at the biliary diseases pathogenesis a different angle.

